KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Common Equity (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Common Equity data on record, last reported at $10.3 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 3.39% year-over-year to $10.3 billion; the TTM value through Dec 2025 reached $10.3 billion, up 3.39%, while the annual FY2025 figure was $10.3 billion, 3.39% up from the prior year.
  • Common Equity reached $10.3 billion in Q4 2025 per EW's latest filing, up from $10.2 billion in the prior quarter.
  • Across five years, Common Equity topped out at $10.6 billion in Q2 2025 and bottomed at $4.7 billion in Q1 2021.
  • Average Common Equity over 5 years is $7.3 billion, with a median of $6.6 billion recorded in 2023.
  • Peak YoY movement for Common Equity: fell 0.5% in 2022, then soared 48.8% in 2024.
  • A 5-year view of Common Equity shows it stood at $5.8 billion in 2021, then fell by 0.5% to $5.8 billion in 2022, then rose by 15.72% to $6.7 billion in 2023, then skyrocketed by 48.8% to $10.0 billion in 2024, then grew by 3.39% to $10.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $10.3 billion in Q4 2025, $10.2 billion in Q3 2025, and $10.6 billion in Q2 2025.